Skip to main content

Resveratrol, wine, and cancer: an update


A recent study on the effects of resveratrol on prostate cancer highlights one of the tantalizing aspects of this red wine antioxidant: a long list of potential anti-cancer properties. It must be pointed out however that nearly all of the evidence for this comes from laboratory research, and though there are some clinical trials in progress it is premature to claim anti-cancer benefits for resveratrol supplements. But if any of it pans out it could lead to significant breakthroughs.

One of the things that make resveratrol so intriguing as an anti-cancer agent is that it not only suppresses cancer cell growth but seems to protect normal cells from the toxic effects of cancer treatment. Radiation treatment is a particularly troublesome therapy because of lasting effects on healthy cells in the treatment zone. But several lines of evidence suggest that resveratrol may pull off the ultimate hat trick: protecting the healthy cells while sensitizing cancerous cells to radiation.

This most recent study evaluated resveratrol as a ‘radiosensitizing” agent on a “radioresistant” clone of prostate cancer cells in culture.  (Again, not an animal study or human clinical trial.) This confirms findings of earlier studies on prostate cancer, but other tumor lines exhibit a similar response to resveratrol. One intriguing example is glioblastoma, a particularly aggressive form of brain cancer. [reference]  Melanoma cells may do likewise [reference] as do some types of lung cancer [reference].

Clinical evidence however points to a role for wine consumption. In a large series  from Italy,  patients undergoing radiation treatment for breast cancer had less irritation of the skin (called radiodermatitis) if they consumed red wine regularly. What is notable about this is that there isn’t enough resveratrol in wine to explain the effect. This is in fact the central dilemma about resveratrol as a candidate for all the healthy things that red wine does: lab studies show a plausible cause-effect explanation for observed inverse correlations between wine and disease, yet the amounts required to produce the effect are far more than what is available by consuming wine.

So what conclusion can we draw from this? First, much work needs to be done in the laboratory and the clinic before we can say definitively that resveratrol (or a derivative) is a useful adjunct to cancer treatment. Wine consumption generally correlates with reduced risk of cancer, in a J-shaped curve with the maximum benefit at moderate levels of consumption and increased risk with heavy consumption. It just doesn’t appear that this has much to do with resveratrol.

Comments

  1. This comment has been removed by the author.

    ReplyDelete
  2. I will tell my friends about this good blog for them to read. I am sure they will like it so much because it contains much useful information for us.

    Retin-a cream

    ReplyDelete

Post a Comment

Popular posts from this blog

Revisiting resveratrol: new findings rekindle anti-aging debate

Just when we thought the bloom was off the rosé for resveratrol, the anti-oxidant polyphenol from red wine with multiple anti-aging properties, along comes new research giving life to the debate. But first a bit of background: As I detailed in my book Age Gets Better with Wine , it is well-documented that wine drinkers live longer and have lower rates of many diseases of aging. Much or the credit for this has been given to resveratrol, though there isn’t nearly enough of it in wine to explain the effects. Nevertheless, I dubbed it the “miracle molecule” and when it was reported to activate a unique life-extension phenomenon via a genetic trigger called SIRT, an industry was born, led by Sirtris Pharmaceuticals, quickly acquired by pharma giant Glaxo. The hope was that resveratrol science could lead to compounds enabling people to live up to 150 years and with a good quality of life. But alas, researchers from other labs could not duplicate the results, and clinical studies disa...

new resveratrol revelations

What a year it has been for resveratrol, the polyphenol molecule from red wine. Last year at this time it was the toast of the town, having been credited with triggering a metabolic change leading to increased lifespan in experimental models, then catapulted into the limelight as a potential cancer cure with clinical trials under the auspices of pharma giant GlaxoSmithKline. Sales of resveratrol supplements were skyrocketing, with audacious claims about weight loss, brain power, and longevity, never mind that none of this had been proven in humans. But with the new year came new controversy. Two of Glaxo’s competitors, Pfizer and Amgen, published their own studies on resveratrol, concluding that the longevity effect was false, an artifact of the testing method. What few clinical trials there are in humans revealed that it is poorly absorbed and doesn’t last very long in the body anyway. Then in November Glaxo abruptly announced the suspension of the clinical trial and all further devel...